SWX:SDZPharmaceuticals
Sandoz Group (SWX:SDZ) Expands Biosimilars And GLP1 Reach, Is The Upside Already Priced In?
Sandoz Group (SWX:SDZ) just packed two key updates into a single week, pairing a global emicizumab biosimilar collaboration with mAbxience and fresh Health Canada approval for Sandoz Semaglutide in type 2 diabetes.
The stock has been volatile in recent weeks, with a 7.4% decline over the past 30 days even as the year-to-date share price return is 19.9% and the 1-year total shareholder return is 45.7%. This suggests momentum has been building as Sandoz Group rolls out new biosimilar deals,...